Core Viewpoint - Hims & Hers Health faced significant stock decline due to regulatory pressures, particularly after pulling its semaglutide weight-loss pill following legal threats from Novo Nordisk and the FDA, despite strong revenue growth and subscriber expansion [2][7]. Financial Performance - Q3 revenue surged 49% year-over-year to $599 million, exceeding estimates [7][8]. - The subscriber base grew by 21% to 2.5 million users, indicating strong customer acquisition [7][8]. - Adjusted EBITDA increased by 53% to $78.4 million, reflecting improved operational efficiency [8]. Market Reaction - Shares of Hims & Hers dropped 22% at market open on February 9, following the announcement of the regulatory action [2][7]. - The stock has experienced a 43% decline over the past year and a 35% drop in the last month, with technical indicators suggesting oversold conditions [3]. Investor Sentiment - Activity on Reddit's r/WallStreetBets surged, with discussions around the stock's regulatory challenges and potential recovery, showing a sentiment score rebounding to 70 [4][5]. - The most engaged post regarding the company's regulatory issues received significant interaction, indicating heightened interest among retail traders [4].

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. ...

Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.By [George Glover]ShareResize---ReprintsIn this a ...

Earnings Overview - More than half of the S&P 500 companies have reported Q4 earnings, with 79% of the 293 companies beating expectations [1] - S&P earnings growth is projected to increase by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth [1] - Excluding the Magnificent Seven technology stocks, Q4 earnings are expected to rise by +4.6% [1] Economic Indicators - The Q4 employment cost index is expected to rise by 0.8% [2] - December retail sales are anticipated to increase by +0.4% month-over-month [2] - January nonfarm payrolls are expected to rise by +69,000, with the unemployment rate remaining at 4.4% [2] - January average hourly earnings are projected to increase by +0.3% month-over-month and +3.7% year-over-year [2] - Initial weekly unemployment claims are expected to decrease by -7,000 to 224,000 [2] - January CPI is expected to rise by +2.5% year-over-year [2] Market Movements - The S&P 500 Index is up +0.46%, the Dow Jones is up +0.09%, and the Nasdaq 100 is up +0.61% [6] - Overseas markets are also showing positive movements, with the Euro Stoxx 50 up +0.66% and Japan's Nikkei Stock 225 up +3.89% [7] Sector Performance - Chip makers and AI-infrastructure stocks have rebounded, with Nvidia up more than +3% and AMD, Broadcom, and Western Digital up more than +2% [12] - Mining stocks are performing well, with gold prices up more than +1% and silver prices up more than +6% [13] - AppLovin is up more than +13% after positive client performance news [13] - Oracle is up more than +9% following an upgrade to buy from neutral [14] Company-Specific News - Dynatrace reported Q3 revenue of $515.5 million, exceeding consensus estimates, and raised its full-year revenue forecast [15] - Kyndryl Holdings is down more than -54% after reporting lower-than-expected Q3 revenue and cutting its profit estimate [16] - Hims & Hers Health is down more than -23% after halting sales of a new product [17] - Monday.com is down more than -21% after forecasting lower Q4 revenue [17]

Morning Trade Live. Let's focus on the latest development in the weight loss drug trade. Novo Nordisk is high this morning and hims and hers is moving in the other direction quite substantially.After Hims pulled its generic wegovy pill. Both stocks have had a rough start to 2026, but today's move is a bright spot for Novo investors, so that is the focus of the morning trade. Joining us now for a closer look is Marley Kayden.Very good morning. Happy Monday Marley. So a nice shot in the arm now for Novo.It ne ...

Group 1 - The U.S. stock market showed mixed results, with major indices fluctuating and most Chinese concept stocks declining [1] - Nvidia experienced a significant intraday surge, rising over 4%, with Goldman Sachs analysts projecting Q4 2025 revenue to reach $67.3 billion, exceeding market expectations [3] - Oracle's stock surged nearly 9.6%, marking its largest intraday gain since December of the previous year, following an upgrade from Davidson Investment Bank from "neutral" to "buy" [3] Group 2 - Storage stocks weakened, with Micron Technology falling nearly 2.5% and SanDisk dropping over 1.4%, as Nvidia may exclude Micron's HBM4 from the first-year production of its Rubin architecture [5] - The weight loss drug sector saw gains, with Novo Nordisk rising over 5% and Eli Lilly increasing nearly 1%, while Hims & Hers plummeted over 25% due to a lawsuit related to a generic version of semaglutide [5] - The gold and silver markets rebounded significantly, with spot gold rising over 1.4% to nearly $5,040 per ounce and spot silver increasing over 5% to $81.696 per ounce [5][6] Group 3 - International oil prices saw a short-term rise, with WTI crude oil and ICE Brent crude both increasing by 1%, and WTI crude surpassing $64 per barrel [6] - Upcoming U.S. non-farm payroll and CPI reports are expected to provide crucial insights into the Federal Reserve's monetary policy direction, with potential for significant market volatility if the data indicates "weak employment + stubborn inflation" [7] Group 4 - The UK faced a "triple whammy" in its stock, bond, and currency markets, with the FTSE 100 index and GBP/EUR exchange rate both plummeting, and the 10-year government bond yield approaching its highest point since November of the previous year [9] - The resignation of two senior officials from the UK Prime Minister's office within 24 hours has raised concerns about political stability, which may impact market confidence [9]

Quick Read How Could Management Fail So Badly One Of The Worst Performing Stocks Not Going To Get Better Investors rethink 'hands off' investing and decide to start making real money Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock is down 47% in the previous year, and 29% so far this year. Buyers need to beware that they are not catching a falling knife. Matters are worse for p ...

| Hims & Hers Health Inc-A (Ai) [ Q | | | --- | --- | | HIMS | | | 16.350 16.923 >> | 17.825 最高 17.900 最低 | | 3.25亿 -26.49% -6.097 快手 | 8.05% 总量 1833万股 金额 | | 盘前 09:30 美东 V | 17.830 -5.190 -22.55% | | 国 年报预披露: 于2026-02-23(美东)盘后披露2025财年年报 ( ... ● | | | 均价:17.712 最新:16.923 -6.097 -26.49% | | | 29.561 | | | 300 9:36 16.950 | | | 9:36 16.950 141 | | | 23.020 - 9:36 16.9601 100 | | | 9:36 16.960 100 | | | 9:36 16.960 125 | | | 100 9:36 16.9234 | | | 9:36 16.940↑ 100 | | | 9:36 16.960↑ 500 | | | -28.42% 9:36 16.9 ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.Novo Nordisk’s Legal Move ExplainedNovo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.Hims c ...